Merck Stock Forecast for 2022 - 2025 - 2030
Updated on 05/25/2022
The average price target of $95.00 for Merck's stock set by nineteen distinguished analysts in recent weeks would represent a potential upside of approximately 0.38% from the last closing price in May, 2022 if reached by the end of the year. This potential increase is based on a high estimate of $115.00 and a low estimate of $76.00. If you want to buy MRK stock, it might be a good idea to look at its competitors too.
0.38% Upside
Merck Fair Value Forecast for 2022 - 2025 - 2030
In the past three years, Merck's Fair Value has moderately grown, increasing from $65.71 to $91.14 – a growth of 38.71%. The next year looks very promising for Merck, with analysts predicting Fair Value of $110.22 – an increase of 20.93%. Over the next nine years, experts anticipate that MRK's Fair Value will grow at a rate of 25.91%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
3
|
$181.40 | $187.12 | 1.98% | 16 |
| LLY Stock Forecast | Eli Lilly and | Outperform |
5
|
$305.96 | $281.95 | 4.92% | 12 |
| ABBV Stock Forecast | AbbVie | Outperform |
6
|
$149.11 | $152.52 | 12.5% | 19 |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
3
|
£104.94 | £136.08 | 39% | 13 |
| DHR Stock Forecast | Danaher | Outperform |
5
|
$252.00 | $339.17 | 32.94% | 7 |
Merck Revenue Forecast for 2022 - 2025 - 2030
In the past three years, Merck's Revenue has moderately grown, increasing from $42.29B to $48.70B – a growth of 15.16%. The next year looks very promising for Merck, with analysts predicting Revenue of $57.19B – an increase of 17.43%. Over the next nine years, experts anticipate that MRK's Revenue will grow at a rate of 5.67%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| BMY Stock Forecast | Bristol-Myers Squibb | Outperform |
8
|
$77.13 | $76.69 | 1.13% | 16 |
| AMGN Stock Forecast | Amgen | Hold |
6
|
$251.89 | $246.46 | -0.75% | 13 |
| GSK Stock Forecast | GlaxoSmithKline | Outperform |
1
|
£17.64 | £16.08 | 2.04% | 11 |
Merck Dividend per Share Forecast for 2022 - 2025 - 2030
In the last three years, Merck's DPS has grown by 35.42%, from $1.92 to $2.60. For the next year, analysts are expecting DPS to reach an unimpressive $2.85 – an increase of 9.62%. Over the next nine years, experts predict that DPS will grow by 23.08%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| CSL Stock Forecast | CSL | Outperform |
4
|
$266.28 | $228.01 | -14.01% | 10 |
| MMM Stock Forecast | 3M | Hold |
5
|
$145.75 | $188.41 | 9.98% | 17 |
| GE Stock Forecast | General Electric | Outperform |
2
|
$74.52 | $121.44 | 43.59% | 13 |
Merck Free Cash Flow Forecast for 2022 - 2025 - 2030
In the last three years, Merck's Free Cash Flow has grown by 16.3%, rising from $8.31B to $9.66B. For next year, analysts predict earnings per share of $15.51B, which would mean an increase of 60.52%. Over the next nine years, experts predict that Merck's Free Cash Flow will grow at a rate of 64.45%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| GILD Stock Forecast | Gilead Sciences | Outperform |
5
|
$64.35 | $75.96 | 6.45% | 19 |
| BDX Stock Forecast | Becton, Dickinson and | Outperform |
5
|
$257.45 | $270.20 | 10.7% | 3 |
| BAYN Stock Forecast | Bayer | Outperform |
5
|
63.29€ | 67.79€ | 20.08% | 14 |
Merck Net Income Forecast for 2022 - 2025 - 2030
In the past three years, Merck's Net Income has seen a tremendous increase, going from $6.22B to $13.05B – an increase of 109.79%. Next year, analysts are expecting Net Income to reach $18.42B – an increase of 41.16%. Over the next nine years, the forecast is for Net Income to grow by 29.43%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| BAS Stock Forecast | BASF | Outperform |
5
|
48.76€ | 78.27€ | 31.26% | 16 |
| ILMN Stock Forecast | Illumina | Outperform |
3
|
$240.26 | $376.81 | 45.68% | 0 |
| ALC Stock Forecast | Alcon | Outperform |
0
|
CHF79.00 | CHF0.00 | 15.3% | 14 |
Merck EBITDA Forecast for 2022 - 2025 - 2030
In the last three years, Merck's EBITDA has grown by 29.8%, rising from $14.62B to $18.98B. For next year, analysts predict earnings per share of $24.07B, which would mean an increase of 26.84%. In 2030, professionals predict that Merck's EBITDA will decrease by 3.86%, to just $18.25B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| BAX Stock Forecast | Baxter International | Outperform |
5
|
$73.90 | $92.47 | 21.79% | 3 |
| A Stock Forecast | Agilent Technologies | Outperform |
7
|
$124.41 | $172.40 | 28.61% | 2 |
| IDXX Stock Forecast | IDEXX Laboratories | Outperform |
8
|
$362.16 | $648.29 | 52.56% | 2 |
Merck EBIT Forecast for 2022 - 2025 - 2030
In the past three years, Merck's EBIT has seen significant growth, rising from $10.10B to $15.86B – a growth of 56.97%. In the next year, analysts believe that EBIT will reach a reasonable $21.68B – an increase of 36.73%. For the next nine years, the forecast is for EBIT to grow by 23.04%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| 4503 Stock Forecast | Astellas Pharma | Outperform |
2
|
¥1.80k | ¥0.00 | 33.33% | 0 |
| HOLX Stock Forecast | Hologic | Outperform |
2
|
$78.39 | $78.91 | 0.78% | 12 |
| FRE Stock Forecast | Fresenius SE & Co. KGaA | Outperform |
6
|
32.31€ | 50.04€ | 23.8% | 6 |
Merck EPS Price Prediction Forecast for 2022 - 2025 - 2030
In the past three years, Merck's EPS has moderately grown, increasing from $4.34 to $6.02 – a growth of 38.71%. The next year looks very promising for Merck, with analysts predicting EPS of $7.28 – an increase of 20.93%. Over the next nine years, experts anticipate that MRK's EPS will grow at a rate of 25.91%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| INCY Stock Forecast | Incyte | Outperform |
0
|
$75.11 | $95.69 | 23.15% | 10 |
| AKZA Stock Forecast | Akzo Nobel N.V. | Outperform |
4
|
93.92€ | 113.10€ | 15.52% | 13 |
| 4523 Stock Forecast | Eisai | Hold |
0
|
¥6.85k | ¥0.00 | -3.61% | 0 |